Dr Yiping Chen
Senior Research Fellow
Yiping Chen is a senior research fellow at the CTSU, University of Oxford. She qualified in clinical medicine in 1985 at Shanghai Medical University (now Fudan University) and then worked as junior neurologist in University affiliated teaching hospital, Hua-shan hospital in Shanghai. In 1988 she was awarded Sino-British Friendship Scholarship to study in the UK and gained her PhD at the University of Oxford in 1993.
She joined CTSU in 1998 and has worked as study coordinator and senior research fellow in several CTSU-led large clinical trials such as COMMIT/CCS2, SHARP, HPS2-THRIVE, REVEAL. During 2006-2016 she also plays a leading role in running Oxford-China Fellowship programmes which provides residence training in epidemiology, medical statistics and clinical trials methodology for the clinical doctors, public health workers from China.
She is currently leading a multi-disciplinary team in the China Kadoorie Biobank (CKB) of 0.5 million people, responsible for developing strategies and procedures related to validation of electronically reported clinical events and for conducting disease validation and adjudication in collaboration with clinical specialists in China for CKB. Her main research interests are in the fields of clinical epidemiology of cardiovascular diseases, major depression, and sleeping disorders
Association between health insurance cost-sharing and choice of hospital tier for cardiovascular diseases in China: a prospective cohort study.
Levy M. et al, (2024), Lancet Reg Health West Pac, 45
Causal association between snoring and stroke: a Mendelian randomization study in a Chinese population.
Zhu Y. et al, (2024), Lancet Reg Health West Pac, 44
Diabetes and chronic kidney disease in Chinese adults: a population-based cohort study.
Wang X. et al, (2024), BMJ Open Diabetes Res Care, 12
PCSK9 genetic variants and risk of vascular and non-vascular diseases in Chinese and UK populations
CHEN Z. et al, (2024), European Journal of Preventive Cardiology
Associations of diabetes, circulating protein biomarkers, and risk of pancreatic cancer.
Pang Y. et al, (2023), Br J Cancer